On March 26, 2026, MetaVia Inc. (the 'Company') released an updated corporate presentation on its website, which outlines its strategic focus on addressing cardiometabolic diseases, particularly obesity and metabolic dysfunction-associated steatohepatitis (MASH). The presentation emphasizes the significant market potential for its product candidates, particularly DA-1726 and Vanoglipel, which are positioned to capture a share of the rapidly growing therapeutic markets. The obesity market is projected to expand from approximately $10 billion today to between $80 billion and $130 billion by 2030, while the MASH market is expected to reach $20 billion to $35 billion as new treatments gain approval and coverage. The Company’s pipeline includes promising clinical data indicating that DA-1726 has shown a potential best-in-class profile for weight loss and glucose control, with significant reductions in weight and liver stiffness observed in Phase 1 studies. Furthermore, Vanoglipel has met primary endpoints in Phase 2a trials, demonstrating direct liver benefits and significant reductions in HbA1c levels. The updated presentation is intended for use in investor communications and conferences, highlighting the Company’s commitment to transparency and engagement with stakeholders. The information provided is not deemed 'filed' under the Securities Exchange Act, but serves to inform investors of the Company’s strategic direction and clinical progress. The Company is actively seeking partnerships and licensing opportunities to further enhance its market position and drive shareholder value.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.